Carvedilol controlled release - RedHill Biopharma
Alternative Names: Cardio; EG-P042; RHB-101Latest Information Update: 07 Jan 2022
Price :
$50 *
At a glance
- Originator Egalet
- Developer RedHill Biopharma
- Class Antihypertensives; Carbazoles; Ethanolamines; Heart failure therapies; Ischaemic heart disorder therapies; Phenyl ethers; Propanolamines; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha beta adrenergic receptor antagonists; Beta adrenergic receptor antagonists; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Heart failure; Hypertension; Left ventricular dysfunction
Most Recent Events
- 20 May 2020 Assertio Therapeutics has been merged with Zyla Life Sciences to form Assertio Therapeutics
- 28 Jan 2019 No recent reports of development identified for clinical-Phase-Unknown development in Heart-failure in Israel (PO, Controlled release)
- 28 Jan 2019 No recent reports of development identified for clinical-Phase-Unknown development in Hypertension in Israel (PO, Controlled release)